Reversing the effects of androgen‐deprivation therapy in men with metastatic castration‐resistant prostate cancer
Abstract
To investigate whether bipolar androgen therapy (BAT), involving rapid cyclic administration of high‐dose testosterone, as a novel treatment for metastatic castration‐resistant prostate cancer (mCRPC) promotes improvements in body composition and associated improvements in lipid profiles and quality of life.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 07, 2021
- Source ID
- 10.1111/bju.15408
Entities
People
- Catherine Handy Marshall
- Clifford R. Weiss
- Corinne Joshu
- Hua‐ling Tsai
- Jessa Tunacao
- John Barber
- Rakhee Gawande
- Samuel Denmeade
- Varun Danda
Organizations
- Johns Hopkins Bloomberg School of Public Health
- Johns Hopkins University
- National Cancer Institute
- Thomas Jefferson University
- United States Department of Defense